JeffreyZangmeisterMD

Oncology • Columbus, OH

Physician

Join to view full profile

Dr. Zangmeister is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Zangmeister's full profile

Already have an account?

Office
3100 Plaza Properties Blvd
Columbus, OH 43219
Phone+1 614-383-6000

Fax+1 614-383-6001
Is this information wrong?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1984 - 1986
Ohio State University HospitalResidency, Internal Medicine, 1981 - 1984
Ohio State University College of MedicineClass of 1981

Certifications & Licensure

OH State Medical License 1981 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Publications & Presentations

PubMed

35 citations
Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.
Rachel Pearlman, Wendy L. Frankel, Benjamin Swanson, Dan Jones, Weiqiang Zhao, Ahmet Yilmaz, Kristin Miller, Jason Bacher, Christopher Bigley, Lori Nelsen, Paul J. Goo...> ;JCO Precision Oncology. 2021 May 5
6 citations
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ...
Neal J. Meropol, Yang Feng, Jean L. Grem, Mary F. Mulcahy, Paul J. Catalano, John S. Kauh, Michael J. Hall, Joel N. Saltzman, Thomas J. George, Jeffrey Zangmeister, El...> ;Cancer. 2018 Feb 15
132 citations
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
David R. Spigel, Howard A. Burris, F. Anthony Greco, Dianna Shipley, Elke K. Friedman, David M. Waterhouse, Robert C. Whorf, R. Brian Mitchell, Davey B. Daniel, Jeffre...> ;Journal of Clinical Oncology. 2011 Jun 20
172 citations
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
James R. Berenson, John Crowley, Thomas M. Grogan, Jeffrey Zangmeister, Adrienne D. Briggs, Glenn Mills, Bart Barlogie, Sydney E. Salmon> ;Blood. 2002 May 1
45 citations
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial
L. R. Laufman, C. H. Spiridonidis, J. Pritchard, R. Roach, J. Zangmeister, N. Larrimer, T. Moore, M. Segal, J. Jones, T. Patel, L. Gutterman, L. Carman, D. Colborn, J....> ;Annals of Oncology. 2001 Sep 1
23 citations
Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer A Phase II Trial of t...
Karen Kelly, Laura C. Lovato, Paul A. Bunn, Robert B. Livingston, Jeffrey Zangmeister, Sarah A. Taylor, Debasish F. Roychowdhury, John Crowley, David R. Gandara> ;Clinical Cancer Research. 2001 Aug 1
42 citations
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
C. H. Spiridonidis, L. R. Laufman, L. Carman, Timothy Moore, S. Blair, J. Jones, Ch. George, T. Patel, R. Roach, R. Rupert, J. Zangmeister, D. Colborn, J.Ph. Kuebler> ;Annals of Oncology. 2001 Jan 1
Join now to see all